You are currently viewing a new version of our website. To view the old version click .
Biology
  • Correction
  • Open Access

4 August 2025

Correction: Thu et al. Effect of Probiotics in Breast Cancer: A Systematic Review and Meta-Analysis. Biology 2023, 12, 280

,
,
,
,
,
,
and
1
Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
2
Department of Infection Biology & Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 3GE, UK
3
Joint Chulalongkorn University—University of Liverpool PhD Programme in Biomedical Sciences and Biotechnology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
4
Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand
This article belongs to the Special Issue Pharmaceutical and Nutraceutical Manipulation of Gut Microbiota: Focus on Microbiome Characterization, Pharmacology, Diagnostics and Therapeutic Indications

Text Correction

There was an error in the original publication [1]. Data was incorrectly extracted from Table 3 of Juan et al. [53], where we had taken the value for % body fat in the post-probiotic group and compared it to body weight in the post-placebo group. Data has been reanalyzed using the correct value for % body fat in the post-placebo group.
A correction has been made to Section 3.8.

3.8. Percentage Change in Body Fat

Three studies assessed percentage change in body fat (BF%) after probiotics intervention. Use of probiotics reduced BF% in both breast cancer patients and survivors (MD = −1.81; 95% CI: −5.22 to 1.61; p = 0.30; Figure 4A). Subgroup analysis demonstrated that ProLBE supplements significantly reduced the elevation of BF% in breast cancer patients (MD = −4.20; 95% CI: −7.59 to −0.81; p = 0.02) while a smaller decrease in BF% occurred in breast cancer survivors with use of ProLBS capsules (Figure 4B).
As such, a correction has also been made to Table 4 and Figure 4 to reflect the revised analysis.
The corrected Table 4 appears below:
Table 4. Quantitative subgroup analysis for all the included trials.
Table 4. Quantitative subgroup analysis for all the included trials.
Subgroup/Sensitivity AnalysisNumber of TrialsSMD (95% CI)p-ValueHeterogeneity (I2, p-Value)
BMI
Probiotics ± prebioticsProbiotics only20.00 (−0.76, 0.77)0.9973% (0.05)
Combined with FOS3−0.05 (−0.29, 0.20)0.720% (0.99)
Intake duration10 weeks3−0.06 (−0.30, 0.19)0.650% (1.00)
8 weeks20.14 (−0.30, 0.58)0.5319% (0.27)
3 weeks1−0.34 (−0.75, 0.07)0.11N/A
Body weight
Probiotics ± prebioticsProbiotics only20.10 (−1.08, 1.28)0.8788% (0.004)
Combined with FOS2−0.01 (−0.32, 0.30)0.930% (0.54)
Intake duration10 weeks10.08 (−0.34, 0.49)0.73N/A
8 weeks20.27 (−0.57, 1.10)0.5375% (0.04)
3 weeks1−0.47 (−0.88, −0.06)0.03N/A
BF%
Probiotics ± prebioticsProbiotics only1−0.51 (−0.93, −0.09)0.02N/A
Combined with FOS2−0.03 (−0.34, 0.28)0.850% (0.86)
Intake duration10 weeks1−0.00 (−0.42, 0.41)0.98N/A
8 weeks1−0.06 (−0.52, 0.40)0.80N/A
3 weeks1−4.50 (−5.28, −3.72)<0.00001N/A
Waist circumference
Probiotics ± prebioticsProbiotics only14.0 (−1.44, 9.44)0.15N/A
Combined with FOS2−1.10 (−4.52, 2.31)0.530% (0.84)
Intake duration10 weeks1−0.14 (−0.56, 0.28)0.360% (1.00)
8 weeks20.19 (−0.24, 0.63)0.3918% (0.27)
Abbreviations: BMI, body mass index; BF%, percentage change in body fat; FOS, fructo-oligosaccharides; N/A, not available.
The corrected Figure 4 appears below:
Figure 4. Meta-analysis for (A) percentage change in body fat (BF%) percent and (B) BF% by probiotic type.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Thu, M.S.; Ondee, T.; Nopsopon, T.; Farzana, I.A.K.; Fothergill, J.L.; Hirankarn, N.; Campbell, B.J.; Pongpirul, K. Effect of Probiotics in Breast Cancer: A Systematic Review and Meta-Analysis. Biology 2023, 12, 280. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.